{"&cites=13816359046575105945&as_sdt=2005&sciodt=0,5&hl=en":[{"title":"Sample size calculations in clinical research","url":"https://books.google.com/books?hl=en&lr=&id=XJ_SBQAAQBAJ&oi=fnd&pg=PP1&ots=PgUntjEeLG&sig=Lcq6ZKzB6m92UpekMj9W98schCE","authors":["SC Chow","SC Chow H Wang","SC Chow H Wang J Shao"],"year":2007,"numCitations":1381,"pdf":"https://www.academia.edu/download/47408260/j.1467-985x.2008.00538_3.x20160721-10196-1dkzub1.pdf","citationUrl":"http://scholar.google.com/scholar?cites=9133863530016594428&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:_NmIvXwAwn4J:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=9133863530016594428&hl=en&as_sdt=2005&sciodt=0,5","publication":"books.google.com","p":1,"exp":1596897535959},{"title":"Bayesian adaptive methods for clinical trials","url":"https://books.google.com/books?hl=en&lr=&id=_Wz0RlH6NssC&oi=fnd&pg=PP1&ots=_MZsYhcIqd&sig=qEbeCYzryT6fCOxZ6BYexqXLHSw","authors":["SM Berry","SM Berry BP Carlin","SM Berry BP Carlin JJ Lee","SM Berry BP Carlin JJ Lee P Muller"],"year":2010,"numCitations":439,"citationUrl":"http://scholar.google.com/scholar?cites=3004134607848268104&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:SOFAXoLUsCkJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=3004134607848268104&hl=en&as_sdt=2005&sciodt=0,5","publication":"books.google.com"},{"title":"Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas","url":"https://www.sciencedirect.com/science/article/pii/S0959804901003987","authors":["M Van Glabbeke","M Van Glabbeke J Verweij","M Van Glabbeke J Verweij I Judson…"],"year":2002,"numCitations":399,"citationUrl":"http://scholar.google.com/scholar?cites=9881594316852735068&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:XKyGHq15IokJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=9881594316852735068&hl=en&as_sdt=2005&sciodt=0,5","publication":"Elsevier"},{"title":"Adaptive design methods in clinical trials","url":"https://books.google.com/books?hl=en&lr=&id=E6bMBQAAQBAJ&oi=fnd&pg=PP1&ots=NdPUwgtZ_-&sig=d5OkpNl-IUic9SPufcc5LsIUiw8","authors":["SC Chow","SC Chow M Chang"],"year":2011,"numCitations":298,"pdf":"https://www.researchgate.net/profile/Mark_Chang/publication/224773242_Adaptive_design_methods_in_clinical_trials_2nd_revised_ed/links/555b4bbb08ae91e75e7642cf/Adaptive-design-methods-in-clinical-trials-2nd-revised-ed.pdf","citationUrl":"http://scholar.google.com/scholar?cites=6904788711151292841&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:qdFM6b-80l8J:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=6904788711151292841&hl=en&as_sdt=2005&sciodt=0,5","publication":"books.google.com"},{"title":"Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with …","url":"https://ascopubs.org/doi/abs/10.1200/jco.2004.01.140","authors":["O Bouché","O Bouché JL Raoul","O Bouché JL Raoul F Bonnetain…"],"year":2004,"numCitations":295,"pdf":"/scholar?output=instlink&q=info:0Ko3lfo7wj0J:scholar.google.com/&hl=en&as_sdt=2005&sciodt=0,5&scillfp=14213467362076824494&oi=lle","citationUrl":"http://scholar.google.com/scholar?cites=4450185329226787536&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:0Ko3lfo7wj0J:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=4450185329226787536&hl=en&as_sdt=2005&sciodt=0,5","publication":"ascopubs.org"},{"title":"Sample size tables for exact single‐stage phase II designs","url":"https://onlinelibrary.wiley.com/doi/abs/10.1002/sim.721","authors":["RP A'hern"],"year":2001,"numCitations":271,"pdf":"http://stat.ethz.ch/education/semesters/as2011/bio/ahernSampleSize.pdf","citationUrl":"http://scholar.google.com/scholar?cites=6955946939253707207&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:x9GuFuN8iGAJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=6955946939253707207&hl=en&as_sdt=2005&sciodt=0,5","publication":"Wiley Online Library"},{"title":"Phase II study of capecitabine and oxaliplatin in first-and second-line treatment of advanced or metastatic colorectal cancer","url":"https://ascopubs.org/doi/abs/10.1200/jco.2002.07.087","authors":["MM Borner","MM Borner D Dietrich","MM Borner D Dietrich R Stupp","MM Borner D Dietrich R Stupp R Morant…"],"year":2002,"numCitations":210,"citationUrl":"http://scholar.google.com/scholar?cites=9345208439320179939&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:43SpAZDZsIEJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=9345208439320179939&hl=en&as_sdt=2005&sciodt=0,5","publication":"ascopubs.org"},{"title":"Phase II trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck","url":"https://ascopubs.org/doi/abs/10.1200/jco.2002.20.6.1593","authors":["BS Glisson","BS Glisson BA Murphy","BS Glisson BA Murphy G Frenette","BS Glisson BA Murphy G Frenette FR Khuri…"],"year":2002,"numCitations":156,"citationUrl":"http://scholar.google.com/scholar?cites=12910073145173283866&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:GhRdAiDLKbMJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=12910073145173283866&hl=en&as_sdt=2005&sciodt=0,5","publication":"ascopubs.org"},{"title":"Optimal three‐stage designs for phase II cancer clinical trials","url":"https://onlinelibrary.wiley.com/doi/abs/10.1002/(SICI)1097-0258(19971215)16:23%3C2701::AID-SIM704%3E3.0.CO;2-1","authors":["TT Chen"],"year":1997,"numCitations":143,"citationUrl":"http://scholar.google.com/scholar?cites=11889323841134999391&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:Xzdvigpd_6QJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=11889323841134999391&hl=en&as_sdt=2005&sciodt=0,5","publication":"Wiley Online Library"},{"title":"Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma","url":"https://www.nature.com/articles/6605580/","authors":["CH Hsu","CH Hsu TS Yang","CH Hsu TS Yang C Hsu","CH Hsu TS Yang C Hsu HC Toh","CH Hsu TS Yang C Hsu HC Toh RJ Epstein…"],"year":2010,"numCitations":140,"pdf":"https://www.nature.com/articles/6605580/","citationUrl":"http://scholar.google.com/scholar?cites=14328667671816174557&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:3fs5u1Sn2cYJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=14328667671816174557&hl=en&as_sdt=2005&sciodt=0,5","publication":"nature.com"}]}